The following is a summary of the Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript:
Financial Performance:
Travere recorded Q1 2024 total revenue of $41.4 million, up from $30.9 million in the same period in 2023.
The company sees a net loss of $136.1 million, or $1.76 per basic share, more significant than last years' $86.3 million or $1.27 per basic share.
The firm's cash and cash equivalents and marketable securities stood at $441 million as of March 2024.
Business Progress:
FILSPARI continues to grow in the US market with 35% growth over the last quarter.
The supplemental New Drug Application (sNDA) of FILSPARI is priority-reviewed by the FDA.
The Phase 3 HARMONY study has been initiated for pegtibatinase, projected to become the new standard in the HCU market.
The growth of FILSPARI will continue to be driven by improved labeling and KDIGO guidelines.
The company has pursued other paths for FSGS treatment and started the Phase III Harmony Study related to the $65 million in-process R&D expense.
More details: Travere Therapeutic IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.